GV20 Therapeutics
Caibin Sheng is a Senior Scientist at GV20 Therapeutics, responsible for leading projects and supporting clinical development with a focus on data science and trial design. Prior to joining GV20 Therapeutics, Caibin worked at Novartis Institutes for BioMedical Research as a Discovery Postdoctoral Fellowship, where Caibin developed deep learning software for multi-omics data analysis. Caibin also has experience as a Postdoctoral Fellow at Technische Universität Darmstadt, focusing on cell-to-cell heterogeneity and live-cell imaging. Caibin holds a PhD in Single Cell Biology, Computational Biology, and Genome Editing from Humboldt-Universität zu Berlin.
This person is not in any offices
GV20 Therapeutics
1 followers
GV20 Therapeutics is the US branch of GV20 Oncotherapy. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.